1 November 2022 - - US-based pharmaceutical company Receptor Life Sciences is expanding the potential clinical utility of RLS103 into epilepsy. A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application, the company said.

The Phase 1b randomized, double-blind, placebo-controlled, crossover study will evaluate RLS103 in patients with photosensitive epilepsy as a model for REST.

RLS103, a dry powder inhaled cannabidiol, is a first-in-class drug/device combination product for the acute treatment of psychiatric and neurological disorders. Epilepsy study startup is underway.

According to the Epilepsy Foundation, seizure disorder affects about 3.4m people in the United States.

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments.

Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience.